Back to Awarded Treatment Trials


Awarded Trial: 01T-099

Grant ID

01T-099

Illness

Schizophrenia

Primary Drug/Intervention

Risperidone

Primary Dosage

0.5mg/d - 20mg/d

Secondary Drug Intervention

Olanzapine

Secondary Dosage

2.5mg/d-20mg/d

Other Drug/Intervention

Molindone

Other Dosage

10mg/d-140mg/d

Status

Completed

Investigator

McClellan

Sample Size

120

Duration of Study Period for Each Subject

8-44 weeks

Outcome Measurements

CGI, KID-SCID, PANSS, BPRS-C, MOSES, EPSE, SAEPS, Barnes Akathisia Scales, AIMS, CGAS, YSR, CBCL, CAFAS, QLS, WRAT

Results

N/A

Publication

Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, Lieberman JA. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry. 2008 Nov;165(11):1420-31.

Link

http://www.ncbi.nlm.nih.gov/pubmed/18794207

PI Name

Jon McClellan

Degree

MD

Center

Children's Hospital, Department of Child Psychiatry

Institution

University of Washington

Address

Box 359300, CH-13, 4800 Sand Point Way NE

City or Town

Seattle

State or Province

WA

Zip or Postal Code

98105

Country

USA

Email Address

drjack@u.washington.edu